Clinical Trials Logo

Clinical Trial Summary

Kawasaki disease (KD) is an acute systemic vasculitic syndrome with coronary tropism.

It has been reported worldwide, but it is ten times more common in Asian population. The annual incidence in children under 5 years in Europe is estimated at 8 to 100000. It is the second vasculitis of the child by its frequency after rheumatoid purpura. It occurs in 80% of cases between 1 and 5 years, with a maximal incidence around the age of 12 months.

It may results in acquired heart disease in children in developed countries, and may be the cause of premature coronary artery disease in adulthood.

A polymorphism was recently associated with the occurrence of disease in a Japanese and U.S population. (C allele of SNP itpkc_3, with a risk multiplied by 2). However, data are conflicting on this issue and the prevalence of this allel is unknown in North America and Europe populations.

The clinical picture of KD associate a persistent fever and an antipyretics resistance with mucocutaneous signs and bulky cervical lymphadenopathy usually unilateral. Diagnosis is confirmed by the presence of five clinical signs (major criteria). The presence of inconsistent coronary lesions in cardiac ultrasound can confirm the diagnosis.

KD can resolve spontaneously with no treatment. The severity of the disease is primarily related to complications of coronary aneurysms in acute or chronic stages.

Several arguments support the fact that adult patients have diffuse vascular lesions different from aneurysmal lesions initially described in childhood.

Despite abundance of publications on KD, there is no prospective or retrospective study which explored anomalies resulting from KD in adult subjects.

Therefore, this project will describe the patient's vascular evolution, the prevalence of atherosclerotic lesions and to determine the biological and functional abnormalities, markers of accelerated atherosclerosis.

Hypothesis : A history of Kawasaki disease represents a cardiovascular risk factor in adulthood.

The main objective is to evaluate the prevalence of atherosclerotic lesions, their extent and their severity in adults with a history of KD in childhood compared to a control population.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01440075
Study type Interventional
Source Hospices Civils de Lyon
Contact
Status Completed
Phase N/A
Start date October 10, 2011
Completion date April 13, 2015

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05911386 - Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
Recruiting NCT02951234 - A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease N/A
Active, not recruiting NCT02853266 - Measurement of Antibodies in Adults With a History of Kawasaki Disease N/A
Active, not recruiting NCT04747847 - Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease Early Phase 1
Withdrawn NCT04535518 - Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease Phase 3
Recruiting NCT01917721 - Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease Phase 2
Recruiting NCT04656184 - A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment Phase 3
Recruiting NCT03200561 - A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Phase 3
Completed NCT02179853 - Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Phase 1/Phase 2
Withdrawn NCT02980263 - Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Phase 2
Enrolling by invitation NCT02359643 - Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease N/A
Recruiting NCT04278404 - Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Completed NCT00760435 - Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Phase 3
Completed NCT00841789 - A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease Phase 2
Not yet recruiting NCT05643651 - Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease Phase 4
Recruiting NCT02114099 - Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Phase 2
Not yet recruiting NCT05091229 - A Blood Test to Diagnose Kawasaki Disease
Completed NCT01431105 - Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Phase 1/Phase 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting NCT06305611 - European and North Indian Cohort of KaWasaki dIsease